U.S. markets closed
  • S&P Futures

    4,219.00
    +5.25 (+0.12%)
     
  • Dow Futures

    33,807.00
    +46.00 (+0.14%)
     
  • Nasdaq Futures

    14,139.00
    +9.00 (+0.06%)
     
  • Russell 2000 Futures

    2,283.50
    +2.60 (+0.11%)
     
  • Crude Oil

    73.64
    -0.02 (-0.03%)
     
  • Gold

    1,786.20
    +3.30 (+0.19%)
     
  • Silver

    25.96
    -0.07 (-0.25%)
     
  • EUR/USD

    1.1910
    -0.0014 (-0.12%)
     
  • 10-Yr Bond

    1.4840
    +0.0340 (+2.34%)
     
  • Vix

    17.89
    -2.81 (-13.57%)
     
  • GBP/USD

    1.3917
    -0.0016 (-0.12%)
     
  • USD/JPY

    110.4450
    +0.1470 (+0.13%)
     
  • BTC-USD

    32,707.12
    -2,252.17 (-6.44%)
     
  • CMC Crypto 200

    787.39
    -62.96 (-7.40%)
     
  • FTSE 100

    7,062.29
    +44.82 (+0.64%)
     
  • Nikkei 225

    28,801.29
    +790.36 (+2.82%)
     

Phathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

FLORHAM PARK, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 10:00 a.m. ET.

Company management will also participate in one-on-one meetings during the virtual conference which runs from June 1-4, 2021.

To access the live webcast and archived recording of the presentation, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recording will be available for 90 days following the event.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company’s website at www.phathompharma.com or follow the Company on social media: LinkedIn at www.linkedin.com/company/phathompharma and Twitter @PhathomPharma.

CONTACTS
Media Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com

Investor Contact:
Todd Branning
1-877-742-8466
ir@phathompharma.com